Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT03491033 |
| Other study ID # |
4-2017-0632 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
March 30, 2018 |
| Last updated |
April 8, 2018 |
| Start date |
August 28, 2017 |
| Est. completion date |
October 31, 2017 |
Study information
| Verified date |
March 2018 |
| Source |
Yonsei University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Tumor response to NAC predicts survival and can be considered a surrogate prognostic marker.
Three tiered chemotherapy response score (CRS) of omental tissue sections showed a
significant association with survival. In patients with CRS 1 or 2, NAC selects a
subpopulation of chemotherapy resistant tumor cells. This study will examine comprehensive
molecular analyses on the residual disease of 104 clinically defined high-grade serous
carcinoma after NAC, including next-generation sequencing on 14 matched pretreatment
biopsies. This information together with immune marker expression and BRCA expression, will
provide a unique opportunity to guide biomarker-driven adjuvant studies targeting these
chemotherapy-resistant tumor cells.
Description:
DNA extracted from FFPE block will be used. Capture sequencing and immunohistochemistry will
be performed.
Immunohistochemistry The formalin-fixed, paraffin-embedded tissue blocks were sectioned at 4
µm thickness onto Superfrost Plus glass slides (Thermo Fisher Scientific, Waltham, MA, USA).
These sections were deparaffinized in xylene and rehydrated through graded alcohols.
Immunohistochemical staining was performed using an automatic immunostaining instrument
(Ventana Benchmark XT; Ventana Medical Systems), according to the manufacturer's
recommendations. Antigen retrieval was performed using a Cell Conditioning Solution (CC1;
Ventana Medical Systems). The sections were incubated with antibodies against PD-L1
(prediluted, clone SP263, Ventana Medical Systems), CD8 (prediluted, clone C8/144B, Dako,
Glostrup, Denmark), PD-1 (1:50, clone NAT105, Cell Marque, Rocklin, CA, USA), Foxp3 (1:50,
clone 236A/E7, Abcam, Cambridge, UK), ICOS/CD278 (1:50, clone SP98, Thermo Fisher
Scientific), and LAG-3 (1:100, clone EPR4392(2), Abcam). After chromogenic visualization
using an ultraView Universal DAB Detection Kit (Ventana Medical Systems), the slices were
counterstained with hematoxylin, dehydrated in graded alcohols and xylene, and then embedded
in mounting solution. Appropriate positive and negative controls were concurrently stained to
validate the staining method.
Targeted Capture Sequencing on NextSeq550 using SureSelect XT Sample Preparation DNA was
extracted from microdissected tumor rich areas from formalin fixed paraffin embedded tumor
sections using DNAeasy kit (QIAGEN, Venlo, Netherlands). Two hundred fifty nanogram of
genomic DNA in 50μl TE buffer was fragmented to a median size of 150bp using the Covaris-E220
AFA instrument (Covaris, Woburn, MA) with the following settings: peak incident power 175
watts, duty factor 10.0%, cycles per burst 200 cycles, run time 500 sec at 4oC. DNA fragments
were evaluated using capillary electrophoresis on High Sensitivity D1000 ScreenTape and
Reagents (TapeSation4200, Cat.No.5067-5584, 5585; Agilent Technologies, Santa Clara, CA,
USA). End repair, 3`-end adenylation and sequencing adapter ligation of DNA fragments were
performed following the manufacture`s protocol (SureSelect XT Reagent kit, HSQ Cat.No.G9611A,
G9611B; Agilent Technologies, Santa Clara, CA, USA). After each steps, fragments were
purified using AMPure XP beads (Cat. No. A63382; Beckman Coulter, High Wycombe, UK). The
resulting DNA was amplified by 14 cycles PCR amplification (SureSelect Herculase Ⅱ Fusion
Enzyme with dNTP Combo 200 RXN kit, Cat. No. 600677; Agilent Technologies, Santa Clara, CA,
USA). The quality of the PCR product was assessed by capillary electrophoresis with DNA1000
TapeScreen and Reagents (TapeSation4200, Cat.No.5067-5582, 5583; Agilent Technologies, Santa
Clara, CA, USA) and the concentration was measured by Qubit 2.0 Fluorometer (Qubit dsDNA HS
Assay Kit, Cat. No. Q32854; Thermofisher Scientific, Inc, Waltham, MA).
Capture and Enrichment Target enrichment was performed according to the manufacturer`s
instructions (SureSelect XT Custom 0.5Mb-2.9Mb library, Cat. No. 5190-4816, 4817; Agilent
Technologies, Santa Clara, CA, USA). The resulting captured libraries with indexing primers
were amplified by 12 cycles of PCR (SureSelect Herculase Ⅱ Fusion Enzyme with dNTP Combo 200
RXN kit, Cat. No. 600677; Agilent Technologies, Santa Clara, CA, USA) and purified again.
Quantity and quality of indexed library DNA were verified by capillary electrophoresis with
High Sensitivity D1000 ScreenTape and Reagents (TapeSation4200, Cat.No.5067-5584, 5585;
Agilent Technologies, Santa Clara, CA, USA) and Qubit 2.0 Fluorometer (Qubit dsDNA HS Assay
Kit, Cat. No. Q32854; Thermofisher Scientific, Inc, Waltham, MA).
Sequencing We diluted resulting libraries to 4nmol/l and pooled by combining 5μl of each
diluted library for normalization. Subsequently, pooled library was denatured into single
strands by using fresh 0.2N NaOH and 200mM Tris-HCl, pH7. A PhiX control was denatured in the
same way. The concentration of final loading library was 1.8pmol/l and Phix was spiked in at
1%. A standard flow cell was loaded on the Illumina NextSeq550 and sequencing was conducted
with 2X100bp paired-end reads using NextSeq550 reagent v2 kit with high-output 300 cycles.
(NextSeq550 System user guide part #15069765-V02 Mar 2016, NextSeq550 Reagent V2 Kit
High-output 300 cycles Cat. No. FC-404-2004; Illumina, CA).
